{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal IMS001",
            "NStudiesAvail": 430108,
            "NStudiesFound": 1,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 1,
            "FieldList": [
                  "BriefSummary",
                  "BriefTitle",
                  "CentralContactEMail",
                  "CentralContactName",
                  "CentralContactPhone",
                  "CentralContactPhoneExt",
                  "CentralContactRole",
                  "CollaboratorClass",
                  "CollaboratorName",
                  "CompletionDate",
                  "CompletionDateType",
                  "Condition",
                  "ConditionAncestorId",
                  "ConditionAncestorTerm",
                  "ConditionBrowseBranchAbbrev",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "BriefSummary": [
                              "This is a Phase 1 study of IMS001, given as a single dose to subjects with Multiple Sclerosis who experience inadequate response and/or intolerability to disease modifying treatments. IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC). MSCs have the potential to modulate disease course."
                        ],
                        "BriefTitle": [
                              "A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis"
                        ],
                        "CentralContactEMail": [
                              "richard.kim@imstem.com"
                        ],
                        "CentralContactName": [
                              "Richard Kim, MD"
                        ],
                        "CentralContactPhone": [
                              "860-281-7836"
                        ],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [
                              "Contact"
                        ],
                        "CollaboratorClass": [
                              "INDUSTRY"
                        ],
                        "CollaboratorName": [
                              "Rho, Inc."
                        ],
                        "CompletionDate": [
                              "December 2027"
                        ],
                        "CompletionDateType": [
                              "Anticipated"
                        ],
                        "Condition": [
                              "Multiple Sclerosis"
                        ],
                        "ConditionAncestorId": [
                              "D000010335",
                              "D000020278",
                              "D000020274",
                              "D000009422",
                              "D000003711",
                              "D000001327",
                              "D000007154"
                        ],
                        "ConditionAncestorTerm": [
                              "Pathologic Processes",
                              "Demyelinating Autoimmune Diseases, CNS",
                              "Autoimmune Diseases of the Nervous System",
                              "Nervous System Diseases",
                              "Demyelinating Diseases",
                              "Autoimmune Diseases",
                              "Immune System Diseases"
                        ],
                        "ConditionBrowseBranchAbbrev": [
                              "BC10",
                              "BC20",
                              "All",
                              "BC23"
                        ],
                        "NCTId": [
                              "NCT04956744"
                        ]
                  }
            ]
      }
}